How big is Iovance Biotherapeutics, Inc.?

As of Jun 18, Iovance Biotherapeutics, Inc. has a market capitalization of 674.55 million, with net sales of 212.67 million and a net profit of -375.36 million over the latest four quarters. The company reported shareholder's funds of 710.40 million and total assets of 910.43 million as of Dec 24.

Market Cap: As of Jun 18, Iovance Biotherapeutics, Inc. has a market capitalization of 674.55 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Iovance Biotherapeutics, Inc. reported net sales of 212.67 million and a net profit of -375.36 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 710.40 million and total assets of 910.43 million.

What does Iovance Biotherapeutics, Inc. do?

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer immunotherapy. As of March 2025, it has a market cap of $674.55 million, with net sales of $49 million and a net loss of $116 million.

Overview:<BR>Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies as novel cancer immunotherapy products, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 49 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -116 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 674.55 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.46 <BR>Return on Equity: -48.88% <BR>Price to Book: 0.88<BR><BR>Contact Details:<BR>Address: 999 Skyway Rd Ste 150, SAN CARLOS CA: 94070-2724 <BR>Tel: ['1 650 2607120', '1 212 8383777'] <BR>Fax: 1 302 7301370 <BR>Website: http://www.iovance.com/

Should I buy, sell or hold Iovance Biotherapeutics, Inc.?

Who are in the management team of Iovance Biotherapeutics, Inc.?

As of March 2022, the management team of Iovance Biotherapeutics, Inc. includes Dr. Iain Dukes (Chairman), Dr. Maria Fardis (CEO), Dr. Athena Countouriotis, Mr. Ryan Maynard, Gen. (Retd.) Merrill McPeak, Mr. Wayne Rothbaum, and Dr. Michael Weiser as independent directors. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Iovance Biotherapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Iain Dukes, Chairman of the Board<BR>- Dr. Maria Fardis, President, Chief Executive Officer and Director<BR>- Dr. Athena Countouriotis, Director<BR>- Mr. Ryan Maynard, Independent Director<BR>- Gen. (Retd.) Merrill McPeak, Independent Director<BR>- Mr. Wayne Rothbaum, Independent Director<BR>- Dr. Michael Weiser, Independent Director<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Is Iovance Biotherapeutics, Inc. overvalued or undervalued?

As of February 28, 2024, Iovance Biotherapeutics, Inc. is considered risky due to overvaluation indicated by a Price to Book Value of 0.89, an EV to Sales ratio of 1.57, a troubling ROCE of -95.61%, and a year-to-date stock performance of -70.27%, significantly underperforming the S&P 500's 12.22% return.

As of 28 February 2024, the valuation grade for Iovance Biotherapeutics, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its valuation outlook. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 0.89 and an EV to Sales ratio of 1.57, which suggest that the market is pricing the stock higher than its book value and sales generation capabilities would justify. Additionally, the ROCE stands at a concerning -95.61%, reflecting severe inefficiencies in capital utilization.<BR><BR>In comparison to its peers, Iovance's valuation metrics are notably unfavorable; for instance, Rhythm Pharmaceuticals, Inc. has a PE ratio of -36.41, while Merus NV shows a PE of -13.18, both indicating greater losses than Iovance. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -70.27% compared to the index's positive 12.22%, reinforcing the notion that the stock is not only overvalued but also struggling in the current market environment.

Is Iovance Biotherapeutics, Inc. technically bullish or bearish?

As of October 3, 2025, Iovance Biotherapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly with a year-to-date return of -70.14%.

As of 3 October 2025, the technical trend for Iovance Biotherapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly. The RSI is bullish on the monthly but shows no signal on the weekly. Moving averages are bearish on the daily, while the KST indicates bullishness weekly but bearishness monthly. The Bollinger Bands are sideways weekly and mildly bearish monthly. <BR><BR>The stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -70.14% versus the S&P's 14.18%, and a one-year return of -78.87% compared to the S&P's 17.82%.